Could cannabis extract ease autism symptoms? new trial seeks answers
NCT ID NCT07257939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a full-spectrum cannabis plant extract called NTI164 can help reduce core autism symptoms (like social challenges and repetitive behaviors) in children and young adults aged 6 to 25. About 98 participants will receive either NTI164 or a placebo for 16 weeks, with researchers tracking changes using standard autism rating scales. The goal is to see if NTI164 is safe and effective for easing autism-related difficulties.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Monash Health
Clayton, Victoria, 3168, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gentle massage and calming sounds: a new bedtime ritual for autistic kids?
- Can a camera catch autism signs in preemie toddlers?
- Light-Up training pods may sharpen reflexes in autistic teen athletes
- Could online coaching for parents boost autistic Children's social skills?
- Can a new curriculum help autistic adults navigate romance?
- Could a phone app help parents of kids with special needs thrive?